Can Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more
Can Fite Biopharma Ltd (CANF) - Total Assets
Latest total assets as of June 2025: ILA7.72 Million ILA
Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) holds total assets worth ILA7.72 Million ILA as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Can Fite Biopharma Ltd - Total Assets Trend (2003–2024)
This chart illustrates how Can Fite Biopharma Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Can Fite Biopharma Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Can Fite Biopharma Ltd's total assets of ILA7.72 Million consist of 98.5% current assets and 1.5% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 52.9% |
| Accounts Receivable | ILA0.00 | 0.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Can Fite Biopharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Can Fite Biopharma Ltd's current assets represent 98.5% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 52.9% of total assets in 2024, down from 70.7% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Can Fite Biopharma Ltd Competitors by Total Assets
Key competitors of Can Fite Biopharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Can Fite Biopharma Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Can Fite Biopharma Ltd generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Can Fite Biopharma Ltd is currently not profitable relative to its asset base.
Can Fite Biopharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.60 | 2.93 | 7.28 |
| Quick Ratio | 3.60 | 2.93 | 8.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA5.50 Million | ILA 3.84 Million | ILA 11.42 Million |
Can Fite Biopharma Ltd - Advanced Valuation Insights
This section examines the relationship between Can Fite Biopharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.34 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -8.7% |
| Total Assets | ILA9.12 Million |
| Market Capitalization | $137.32K USD |
Valuation Analysis
Below Book Valuation: The market values Can Fite Biopharma Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Can Fite Biopharma Ltd's assets decreased by 8.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Can Fite Biopharma Ltd (2003–2024)
The table below shows the annual total assets of Can Fite Biopharma Ltd from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA9.12 Million | -8.70% |
| 2023-12-31 | ILA9.99 Million | +7.61% |
| 2022-12-31 | ILA9.28 Million | -54.16% |
| 2021-12-31 | ILA20.25 Million | +112.67% |
| 2020-12-31 | ILA9.52 Million | +16.50% |
| 2019-12-31 | ILA8.17 Million | +2.79% |
| 2018-12-31 | ILA7.95 Million | +1.53% |
| 2017-12-31 | ILA7.83 Million | -22.96% |
| 2016-12-31 | ILA10.17 Million | -42.24% |
| 2015-12-31 | ILA17.60 Million | +72.78% |
| 2014-12-31 | ILA10.19 Million | +53.54% |
| 2013-12-31 | ILA6.63 Million | +305.74% |
| 2012-12-31 | ILA1.64 Million | -66.65% |
| 2011-12-31 | ILA4.90 Million | -73.56% |
| 2010-12-31 | ILA18.55 Million | -7.74% |
| 2009-12-31 | ILA20.10 Million | -8.06% |
| 2008-12-31 | ILA21.86 Million | -55.32% |
| 2007-12-31 | ILA48.94 Million | +17.18% |
| 2006-12-31 | ILA41.76 Million | +12.60% |
| 2005-12-31 | ILA37.09 Million | +2797.42% |
| 2004-12-31 | ILA1.28 Million | -52.78% |
| 2003-12-31 | ILA2.71 Million | -- |